Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / TMSB4X

TMSB4X

Basics

Aliases:
This biomarker is also known as:
  • TB4X,
  • FX,
  • THYB4,
  • thymosin beta-4,
  • prothymosin beta-4,
  • thymosin β4,
  • thymosin beta 4, X-linked,
  • T beta-4,
  • Fx,
  • TMSB4,
  • PTMB4,
  • thymosin, beta 4, X chromosome,

View in BioMuta

Description…

TMSB4X, or thymosin beta-4, belongs to the thymosin beta family. It is an actin sequestering protein which plays an important role in the regulation of actin polymerization. TMSB4X binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerization. It is also involved in cell proliferation, migration, and differentiation. This gene escapes X inactivation and has a homolog on chromosome Y.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: TMSB4X

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Under Review

Overview

Overexpression of thymosin beta-4 in tumors has been suggested to stimulate lung tumor metastasis by activating cell migration and angiogenesis. The gene expression of thymosin beta-4 was also significantly associated with metastasis in NSCLC patients and it was suggested as a prognostic parameter for NSCLC.

Performance Comment

Thymosin beta-4 belongs to a 9-member panel that provides a quantitative measure of the probability of having lung cancer that goes beyond the histological evaluation of preinvasive lesions. The identified members of the panel are TMSB4X (Thymosin beta-4), Ubiquitin, des-ubiquitin, ACBP, CSTA, Cytochrome C, and MIF.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.